Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.51 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.39 |
| ▸ | TK1 | P04183 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15771583 | 1.00 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL6034458 | 0.92 | DUT (0.53) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL10765602 | 0.90 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL2056622 | 0.90 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL249821 | 0.90 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL28745696 | 0.90 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL51722 | 0.88 | DUT (0.53) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL3340603 | 0.88 | DUT (0.50) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL41471 | 0.88 | DUT (0.50) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL4954183 | 0.88 | DUT (0.53) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385789-A1 | METHODS OF ASSESSING TELOMERES | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2020-12-10 | — | — | US | claimed |
| EP-3676609-A1 | METHODS OF ASSESSING TELOMERES | Children's Medical Research Institute (AU) | 2020-07-08 | — | — | EP | claimed |
| WO-2019040993-A1 | METHODS OF ASSESSING TELOMERES | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2019-03-07 | — | — | WO | claimed |
| US-9644238-B2 | Methods of isolating non-senescent cardiac stem cells and uses thereof | AUTOLOGOUS REGENERATION, LLC (US) | 2017-05-09 | — | — | US | claimed |
| US-20170022242-A1 | NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS | Katholieke Universiteit Leuven, KU LEUVEN R&D (BE) | 2017-01-26 | — | — | US | claimed |
| WO-2015158913-A1 | NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-10-22 | — | — | WO | claimed |
| US-20140051077-A1 | METHODS OF ISOLATING NON-SENESCENT CARDIAC STEM CELLS AND USES THEREOF | AUTOLOGOUS, LLC (US) | 2014-02-20 | — | — | US | claimed |
| EP-2635292-A1 | METHODS OF ISOLATING NON-SENESCENT CARDIAC STEM CELLS AND USES THEREOF | Autologous, LLC (US) | 2013-09-11 | — | — | EP | claimed |
| US-8512696-B2 | Methods of isolating non-senescent cardiac stem cells and uses thereof | AUTOLOGOUS, LLC (US) | 2013-08-20 | — | — | US | claimed |
| WO-2012061491-A1 | METHODS OF ISOLATING NON-SENESCENT CARDIAC STEM CELLS AND USES THEREOF | ANVERSA PIERO (US) | 2012-05-10 | — | — | WO | claimed |
| US-7635467-B2 | Mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2009-12-22 | — | — | US | claimed |
| US-7618621-B2 | Mammalian multipotent neural stem cells and compositions, methods of preparation and methods of administration thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2009-11-17 | — | — | US | claimed |
| US-20030229004-A1 | Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors | PANGENE CORPORATION | 2003-12-11 | — | — | US | claimed |
| WO-1996025147-A1 | LIPOSOME COMPOSITION AND METHOD FOR ADMINISTERING LIPOSOME-LOADABLE DRUGS | SEQUUS PHARMACEUTICALS, INC. (US) | 1996-08-22 | — | — | WO | claimed |
| WO-1996021665-A1 | TURCASARINS, NOVEL EXPANDED PORPHYRINS, AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-07-18 | — | — | WO | claimed |
| US-4780406-A | Flow cytometric measurement of total DNA and incorporated halodeoxyuridine | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1988-10-25 | — | — | US | claimed |
| US-4585736-A | Flow cytometric measurement of total DNA and incorporated halodeoxyuridine | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1986-04-29 | — | — | US | claimed |
| US-20250207177-A1 | METHODS, COMPOSITIONS AND DEVICES FOR SPREADING OF CHROMATIN FIBERS | ERASMUS UNIVERSITY MEDICAL CENTER (NL) | 2025-06-26 | — | — | US | disclosed |
| WO-1996013552-A2 | SUBSTITUTED UNSYMMETRICAL CYANINE DYES WITH SELECTED PERMEABILITY | MOLECULAR PROBES, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022242-A1 | NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS | PNP, NTPCR, ENTPD5 | DUT 45/4885SLC28A1 41/4885SLC28A2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.